Thyrotropin receptor antibodies and Graves' orbitopathy (vol 44, pg 703, 2021)

被引：1
|
作者：
Diana, T. [1 ]
Ponto, K. A. [2 ,3 ]
Kahaly, G. J. [1 ]
机构：
[1] Johannes Gutenberg Univ Mainz, Med Ctr, Mol Thyroid Res Lab, Dept Med 1, D-55101 Mainz, Germany
[2] Johannes Gutenberg Univ Mainz, Med Ctr, Dept Ophthalmol, D-55101 Mainz, Germany
[3] Johannes Gutenberg Univ Mainz, Med Ctr, Ctr Thrombosis & Hemostasis, D-55101 Mainz, Germany
来源：
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION | 2022年 / 45卷 / 01期
关键词：
D O I：
10.1007/s40618-021-01632-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：233 / 233
页数：1
相关论文
共 50 条
  • [41] ELF3-induced miR-182 inhibits adipogenic differentiation in Graves' orbitopathy by targeting thyrotropin receptor
    Wang, Sha
    Chen, Lu
    Xu, Bei
    CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY, 2022, 47 (04) : 308 - 322
  • [42] The prevalence and clinical significance of blocking thyrotropin receptor antibodies in untreated hyperthyroid Graves' disease
    Kim, WB
    Chung, HK
    Park, YJ
    Park, DJ
    Tahara, K
    Kohn, LD
    Cho, BY
    THYROID, 2000, 10 (07) : 579 - 586
  • [43] Measurement of thyrotropin receptor antibodies (TRAK) with a second generation assay in patients with Graves' disease
    Zophel, K
    Wunderlich, G
    Koch, R
    Franke, WG
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2000, 39 (04): : 113 - 120
  • [44] Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves' orbitopathy
    Park, Jungyul
    Kim, Jaehyun
    Kim, Sang Soo
    Choi, Hee-Young
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [45] Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study (vol 108, pg 2065, 2023)
    Biscarini, F.
    Masetti, G.
    Muller, I
    Verhasselt, H. L.
    Covelli, D.
    Colucci, G.
    Zhang, L.
    Draman, M. S.
    Okosieme, O.
    Taylor, P.
    Daumerie, C.
    Burlacu, M-C
    Marino, M.
    Ezra, D. G.
    Perros, P.
    Plummer, S.
    Eckstein, A.
    Salvi, M.
    Marchesi, J. R.
    Ludgate, M.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (02): : e880 - e880
  • [46] THIRD-GENERATION ELISA THYROTROPIN-RECEPTOR ANTIBODY LEVELS AS AN ADJUVANT TOOL TO GUIDE MANAGEMENT OF PATIENTS WITH GRAVES ORBITOPATHY
    Tvito-Green, Ravit
    Reich, Ehud
    Robenshtok, Eyal
    Chodick, Gabriel
    Ron-Kella, Yonina
    Stiebel-Kalish, Hadas
    ENDOCRINE PRACTICE, 2014, 20 (02) : 145 - 149
  • [47] Dynamics of thyroid-stimulating and -blocking antibodies to the thyrotropin receptor in a murine model of Graves' disease
    Muehlberg, T
    Gilbert, JA
    Rao, PV
    McGregor, AM
    Banga, JP
    ENDOCRINOLOGY, 2004, 145 (04) : 1539 - 1545
  • [48] Evaluation of the diagnostic performance of thyroid-stimulating immunoglobulin and thyrotropin receptor antibodies for Graves' disease
    Xu, Shiji
    Shao, Wenqi
    Wu, Qun
    Zhu, Jing
    Pan, Baishen
    Wang, Beili
    Guo, Wei
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2023, 37 (08)
  • [49] The effect of thyrotropin-receptor blocking antibodies on stimulating autoantibodies from patients with Graves' disease
    Lenzner, C
    Morgenthaler, NG
    THYROID, 2003, 13 (12) : 1153 - 1161
  • [50] Thyrotropin receptor antibodies in black South African patients with Graves' disease and their response to medical therapy
    Zouvanis, M
    Panz, VR
    Kalk, WJ
    Joffe, BI
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1998, 21 (11) : 771 - 774
12345